Antibody Drug Conjugate Using CTAT Linker Technology Shows Superior Efficacy in Xenograft Trial

on .

CTATTM is an innovative enzymatic linker technology for conjugating different payloads with antibodies, without affecting their specificity, binding properties or stability. In the presented xenograft trial, the tested CTAT-ADC showed superior efficacy versus a commercially available ADC.

EUCODIS participates in European ERA-IB project ChitoTex

on .

Scope of ChitoTex is to develop and produce new insect chitosan and chitosan based functional coatings for yarns and textile fabrics. The three-year project with seven academic and industry partners is funded through the ERA-NET Scheme of the 7th EU Framework Programme.

EUCODIS Bioscience introduces new panel of Peroxidases

on .

EUCODIS is glad to announce the addition of a new enzyme family to its portfolio of recombinant industrial enzymes. Our collection of more than 20 Peroxidases is carefully selected from 10 subfamilies, and all Peroxidases display unique properties for their utility in chemical, flavor, feed, cosmetics, paper and other industries. EUCODIS Peroxidases use hydrogen peroxide as a co-substrate to catalyze reactions similar to cytochrome P450 oxidoreductases, but eliminating the need for expensive cofactor recycling systems. The enzymes are exclusively available from EUCODIS.